Trevi reports Q3 2026 results, three chronic cough trials now recruiting
Trevi Therapeutics said its Phase 3 OCEAN-2 trial opened in the third quarter and all three active trials are enrolling, with cash into 2030.
SEC filing
1 story
Trevi Therapeutics said its Phase 3 OCEAN-2 trial opened in the third quarter and all three active trials are enrolling, with cash into 2030.
SEC filing